Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / KRYS - Krystal Biotech's Legal Risk: A Layperson's View

KRYS - Krystal Biotech's Legal Risk: A Layperson's View

Krystal Biotech Inc.
  • Krystal Biotech is a pivotal-stage gene therapy company that leverages its novel, re-dosable HSV-vectored gene therapy for serious rare diseases.
  • Top-line phase 3 results of their lead candidate, B-VEC, in dystrophic epidermolysis bullosa (DEB) is expected in Q4, 2021.
  • Some readers expressed concern over an ongoing lawsuit against the company.
  • I look at the relevant documents regarding the lawsuit and share my thoughts.

For further details see:

Krystal Biotech's Legal Risk: A Layperson's View
Stock Information
Company Name: Krystal Biotech Inc.
Stock Symbol: KRYS
Market: NASDAQ
Website: krystalbio.com
Menu
KRYS KRYS Quote KRYS Short KRYS News KRYS Articles KRYS Message Board
Get KRYS Alerts

News, Short Squeeze, Breakout and More Instantly...